Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Accounts Payables: 2016-2025

Historic Accounts Payables for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $10.1 million.

  • Akebia Therapeutics' Accounts Payables fell 25.25% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year decrease of 25.25%. This contributed to the annual value of $15.2 million for FY2024, which is 3.72% up from last year.
  • Akebia Therapeutics' Accounts Payables amounted to $10.1 million in Q3 2025, which was down 12.70% from $11.6 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Accounts Payables registered a high of $42.0 million during Q2 2021, and its lowest value of $9.0 million during Q3 2023.
  • Over the past 3 years, Akebia Therapeutics' median Accounts Payables value was $11.9 million (recorded in 2024), while the average stood at $12.1 million.
  • In the last 5 years, Akebia Therapeutics' Accounts Payables slumped by 54.14% in 2023 and then skyrocketed by 49.30% in 2024.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Accounts Payables stood at $33.6 million in 2021, then slumped by 46.35% to $18.0 million in 2022, then dropped by 18.79% to $14.6 million in 2023, then increased by 3.72% to $15.2 million in 2024, then fell by 25.25% to $10.1 million in 2025.
  • Its Accounts Payables stands at $10.1 million for Q3 2025, versus $11.6 million for Q2 2025 and $12.7 million for Q1 2025.